Edition:
United States

DURECT Corp (DRRX.OQ)

DRRX.OQ on NASDAQ Stock Exchange Global Market

1.32USD
6 Dec 2016
Change (% chg)

-- (--)
Prev Close
$1.32
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
140,988
52-wk High
$2.55
52-wk Low
$1.00

DRRX.OQ

Chart for DRRX.OQ

About

Durect Corporation is a biopharmaceutical company with research and development programs. The Company's products candidates include DUR-928, oral for metabolic/lipid disorders, and DUR-928, injectable for acute organ injuries. Its other product candidates include POSIMIR (controlled release injection of bupivacaine), REMOXY... (more)

Overall

Beta: 1.33
Market Cap(Mil.): $182.93
Shares Outstanding(Mil.): 138.58
Dividend: --
Yield (%): --

Financials

  DRRX.OQ Industry Sector
P/E (TTM): -- 42.71 30.37
EPS (TTM): -0.24 -- --
ROI: -80.85 -0.66 15.17
ROE: -209.20 -1.36 16.51

BRIEF-Durect Corp announces update on DUR-928 development program

* Durect-Report data from cohort 1 of first patient study with DUR-928,single dose provided signals of DUR-928 activity in cirrhotic,non-cirrhotic NASH patients

Oct 31 2016

BRIEF-Durect Corp announces Q3 financial results and update of programs

* Q3 earnings per share view $-0.07 -- Thomson Reuters I/B/E/S

Oct 31 2016

BRIEF-Durect Corp qtrly loss per share $0.07

* Durect corporation announces second quarter 2016 financial results and update of programs

Aug 01 2016

BRIEF-Durect says PDUFA date for remoxy NDA of Sept 25 unchanged

* Says prescription drug user fee act (PDUFA) date for remoxy NDA of September 25, 2016 is unchanged

Jul 01 2016

Earnings vs. Estimates